{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:09:22Z","timestamp":1790701762998,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,10]],"date-time":"2027-02-10T00:00:00Z","timestamp":1802217600000},"content-version":"am","delay-in-days":315,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.lungcan.2026.109310","type":"journal-article","created":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T15:41:50Z","timestamp":1770565310000},"page":"109310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small cell lung cancer"],"prefix":"10.1016","volume":"214","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5487-0453","authenticated-orcid":false,"given":"Kazumasa","family":"Akagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2414-8344","authenticated-orcid":false,"given":"Hirokazu","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5321-1843","authenticated-orcid":false,"given":"Minoru","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Takao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawana","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2748-9418","authenticated-orcid":false,"given":"Hiromi","family":"Tomono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Suyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noritaka","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Umeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Dotsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5026-8078","authenticated-orcid":false,"given":"Hiroshi","family":"Gyotoku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Senju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0373-0618","authenticated-orcid":false,"given":"Shinnosuke","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Soda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Mizowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaya","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Tasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6365-9302","authenticated-orcid":false,"given":"Daisuke","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Komiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Nakatomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9764-5718","authenticated-orcid":false,"given":"Ryo","family":"Toya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Ashizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1429-5706","authenticated-orcid":false,"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.lungcan.2026.109310_b0005","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: a review","volume":"333","author":"Kim","year":"2025","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109310_b0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0169-5002(02)00072-7","article-title":"Staging small cell lung cancer: veterans administration lung study group versus international association for the study of lung cancer\u2013what limits limited disease?","volume":"37","author":"Micke","year":"2002","journal-title":"Lung Cancer"},{"issue":"5 Suppl","key":"10.1016\/j.lungcan.2026.109310_b0015","doi-asserted-by":"crossref","first-page":"e400S","DOI":"10.1378\/chest.12-2363","article-title":"Treatment of small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Jett","year":"2013","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109310_b0020","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM199901283400403","article-title":"Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide","volume":"340","author":"Turrisi","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109310_b0025","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Lancet Oncol."},{"issue":"14","key":"10.1016\/j.lungcan.2026.109310_b0030","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1200\/JCO.2002.12.071","article-title":"Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104","volume":"20","author":"Takada","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.lungcan.2026.109310_b0035","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109310_b0040","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/j.1349-7006.1998.tb00519.x","article-title":"A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex","volume":"89","author":"Hanada","year":"1998","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109310_b0045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1748-717X-7-26","article-title":"Radiosensitization by the novel DNA intercalating agent vosaroxin","volume":"7","author":"Gordon","year":"2012","journal-title":"Radiat. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109310_b0050","first-page":"909","article-title":"Enhancement of radiosensitivity by topoisomerase II inhibitor, amrubicin and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction","volume":"18","author":"Hayashi","year":"2006","journal-title":"Int. J. Mol. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109310_b0055","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10637-006-9012-9","article-title":"Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study","volume":"25","author":"Yana","year":"2007","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.lungcan.2026.109310_b0060","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12885-016-2301-6","article-title":"Randomized phase III trial of amrubicin\/cisplatin versus etoposide\/cisplatin as first-line treatment for extensive small-cell lung cancer","volume":"16","author":"Sun","year":"2016","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109310_b0065","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00280-019-03940-0","article-title":"Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer","volume":"84","author":"Shimada","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109310_b0070","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1200\/JCO.1999.17.9.2681","article-title":"Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma","volume":"17","author":"Bonner","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109310_b0075","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1470-2045(13)70511-4","article-title":"Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study","volume":"15","author":"Kubota","year":"2014","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109310_b0080","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/cas.12875","article-title":"Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited-disease small cell lung cancer","volume":"107","author":"Sekine","year":"2016","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109310_b0085","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/annonc\/mdi081","article-title":"Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer","volume":"16","author":"Ohe","year":"2005","journal-title":"Ann. Oncol."},{"issue":"16","key":"10.1016\/j.lungcan.2026.109310_b0090","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1111\/1759-7714.14555","article-title":"Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-disease small cell lung cancer: protocol of ACIST study","volume":"13","author":"Akagi","year":"2022","journal-title":"Thorac Cancer"},{"issue":"13","key":"10.1016\/j.lungcan.2026.109310_b0095","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1200\/JCO.22.01359","article-title":"High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)\/RTOG 0538","volume":"41","author":"Bogart","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109310_b0100","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(20)30742-7","article-title":"High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial","volume":"22","author":"Gronberg","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109310_b0105","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ijrobp.2019.01.057","article-title":"Trends in IMRT use for limited stage small cell lung cancer: a national cancer database analysis","volume":"104","author":"Hasan","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109310_b0110","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ijrobp.2013.05.040","article-title":"Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer","volume":"87","author":"Shirvani","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109310_b0115","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.prro.2020.02.009","article-title":"Radiation Therapy for small cell lung cancer: an ASTRO clinical practice guideline","volume":"10","author":"Simone","year":"2020","journal-title":"Pract. Radiat. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109310_b0120","first-page":"452","article-title":"Simultaneous integrated dose reduction intensity-modulated radiotherapy effectively reduces cardiac toxicity in limited-stage small cell lung cancer","volume":"20","author":"Luo","year":"2023","journal-title":"Cancer Biol. Med."},{"issue":"18","key":"10.1016\/j.lungcan.2026.109310_b0125","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10184221","article-title":"Real-world incidence of febrile neutropenia among patients treated with single-agent amrubicin: necessity of the primary prophylactic administration of granulocyte colony-stimulating factor","volume":"10","author":"Dotsu","year":"2021","journal-title":"J. Clin. Med."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109310_b0130","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/JTO.0b013e3181e369a8","article-title":"Severe interstitial lung disease associated with amrubicin treatment","volume":"5","author":"Yoh","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109310_b0135","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3389\/fonc.2020.00741","article-title":"Targeted therapies and biomarkers in small cell lung cancer","volume":"10","author":"Taniguchi","year":"2020","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109310_b0140","article-title":"Pembrolizumab plus amrubicin in patients with relapsed SCLC: multi-institutional, single-arm phase 2 study","volume":"2","author":"Akamatsu","year":"2021","journal-title":"JTO Clin Res Rep"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:47:00Z","timestamp":1790700420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226000541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":28,"alternative-id":["S0169500226000541"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109310","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109310","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109310"}}